Clinical trial
Long Term Safety Of GW685698X Via Nasal Biopsy
NCT00224523 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00224523 |
|---|---|
| Title | Long Term Safety Of GW685698X Via Nasal Biopsy |
| Official title | A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD Via Nasal Biopsy in Subjects 18 Years of Age With Perennial Allergic… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rhinitis, Allergic, Perennial |
| Intervention type | Drug |
| Interventions | GW685698X, mometasone furoate |
| Enrollment | 125 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 23, 2005 |
| Last update posted | Oct 28, 2016 |
| Countries | Belgium, Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: